Benedek I H, Blouin R A, McNamara P J
Br J Clin Pharmacol. 1984 Dec;18(6):941-6. doi: 10.1111/j.1365-2125.1984.tb02567.x.
Serum protein and lipid concentrations as well as the serum protein binding of propranolol, diazepam and phenytoin were measured in normal weight and obese volunteers. Concentrations of alpha 1-acid glycoprotein (AAG) in the obese subjects were double that of the lean controls. Conversely, concentrations of high density lipoproteins (HDL) were decreased in the obese group. The serum binding of propranolol was increased in the obese subjects and correlated with serum AAG concentrations. Diazepam binding was slightly decreased in the obese as a result of lower serum albumin concentrations and elevated free fatty acids. The binding of phenytoin was comparable in all of the volunteers. These findings point out some of the complex pathophysiologic changes associated with obesity which may in turn influence drug disposition and hence drug therapy in the obese patient.
在正常体重和肥胖志愿者中测量了血清蛋白质和脂质浓度以及普萘洛尔、地西泮和苯妥英的血清蛋白结合率。肥胖受试者中α1-酸性糖蛋白(AAG)的浓度是瘦对照组的两倍。相反,肥胖组中高密度脂蛋白(HDL)的浓度降低。肥胖受试者中普萘洛尔的血清结合率增加,且与血清AAG浓度相关。由于血清白蛋白浓度降低和游离脂肪酸升高,肥胖者地西泮的结合率略有降低。苯妥英在所有志愿者中的结合情况相当。这些发现指出了一些与肥胖相关的复杂病理生理变化,这些变化反过来可能影响药物处置,从而影响肥胖患者的药物治疗。